POET: Short Interest Holds at 20% as Borrow Cost Collapses

Options positioning confirms the directional lean but lacks urgency. The put/call ratio is running at 0.21, below its 20-day average of 0.24 and over a full standard deviation beneath that mean. That skews toward calls — suggesting the options market is not adding incremental downside pressure. The 52-week range for PCR runs from 0.03 to 0.43; the current reading is toward the lower half, meaning options traders remain more skewed to upside lottery tickets than to protection. It is not a crowded hedge; it is a stock that retail and speculative buyers have used call options to chase, and that thesis is being tested as the price falls further.

The Street is quiet and the analyst data is stale — the most recent target-price action from Northland Capital Markets and Craig-Hallum dates to late 2024, when both lifted targets to the $5.50–$7.00 range. The consensus mean target of $17.50 is almost certainly a legacy artefact from earlier periods and should not be taken at face value against an $8.31 stock. What is more informative is the ORTEX short score, which has held steady near 65 for the past two weeks — elevated but not accelerating. The EPS surprise factor ranks at the 91st percentile, reflecting the four most recent earnings prints where the stock moved sharply higher on results day (gains of 10%, 4%, 20%, and 10% on announcement days). That is a pattern worth noting ahead of the August 12 earnings event. The short score rank at the 5th percentile, however, means 95% of the ORTEX universe carries more short-side pressure relative to its own history — an irony given 20% SI, explained partly by the low cost to borrow dragging the composite score.

Insider activity from the past six weeks is a clear negative signal. Multiple officers sold stock at $14–$15 in early June — a controller, two VPs, and a senior VP collectively disposed of more than $2.8 million of shares. Those sales occurred 70–80% above where the stock trades today. The net insider position over 90 days is technically positive at roughly $4 million in net value, but that figure is dominated by older grants and option exercises rather than open-market buying. No insider has bought since the stock fell below $10.

Correlated peers have diverged sharply this week: AMD rose 8% on the week and HIMX gained 16%, while POET fell 5%. That sector recovery has not lifted the stock, reinforcing that the pressure here is company-specific rather than a semiconductor-wide selloff.

The August 12 earnings print is the next hard catalyst — four consecutive positive announcement-day moves provide a historical base rate to watch, but the distance the stock must travel to close the gap with where insiders sold means the reaction to any guidance will matter more than the headline beat.